Armodafinil interactions
Full monograph for ArmodafinilCheck it against another medicine
Medicines
353 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Citalopram Hydrobromide | Major | Metabolism | Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT… | 9 sources — open the full entry |
| Fentanyl Citrate | Major | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as… | 12 sources — open the full entry |
| Mavacamten | Major | Metabolism | Coadministration with inhibitors of CYP450 2C19 that can also induce CYP450 3A4 may alter the plasma concentrations of mavacamten. | 1 sources — open the full entry |
| Olaparib | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Ranolazine | Major | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. | 12 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Abemaciclib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which… | 2 sources — open the full entry |
| Acalabrutinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Alpelisib | Moderate | Metabolism | Coadministration of alpelisib with inducers of CYP450 3A4 may reduce the plasma concentrations of alpelisib. The proposed mechanism, based on in vitro data, is… | 2 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may increase the plasma concentrations of tricyclic antidepressants (TCAs) in… | 7 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may increase the plasma concentrations of tricyclic antidepressants (TCAs) in…2 documented mechanisms | 18 sources — open the full entry |
| Arformoterol Tartrate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by…2 documented mechanisms | 19 sources — open the full entry |
| Axitinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Beclomethasone Dipropionate + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme. | 4 sources — open the full entry |
| Bromocriptine Mesylate | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bromocriptine. | 4 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTablet | Moderate | Absorption · Metabolism | Concomitant use of orally and rectally administered formulations of budesonide with inducers of CYP450 3A4 may decrease budesonide systemic as well as local… | 2 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Absorption · Metabolism · Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…2 documented mechanisms | 13 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Absorption · Metabolism · Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…2 documented mechanisms | 13 sources — open the full entry |
| Bupropion Hydrochloride | Moderate | Synergy | Translated with DeepL | 4 sources — open the full entry |
| Cabozantinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. | 13 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are…2 documented mechanisms | 18 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration of modafinil (the racemate) or armodafinil (the R-enantiomer) with carbamazepine may result in a reduction in the plasma concentrations and… | 9 sources — open the full entry |
| Cariprazine | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 is expected to alter the pharmacokinetics of cariprazine and its major active metabolites. Cariprazine is… | 4 sources — open the full entry |
| Carisoprodol | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may increase the plasma concentrations of drugs that are primarily metabolized… | 9 sources — open the full entry |
| Cenobamate | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. | 2 sources — open the full entry |
| Cilostazol | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active… | 11 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are…2 documented mechanisms | 19 sources — open the full entry |
| Clobazam | Moderate | Metabolism | Coadministration of clobazam with inhibitors of CYP450 2C19 may significantly increase the plasma concentrations of its active metabolite, N-desmethylclobazam… | 7 sources — open the full entry |
| Clomipramine Hydrochloride | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may increase the plasma concentrations of tricyclic antidepressants (TCAs) in… | 7 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation by the… | 21 sources — open the full entry |
| Clopidogrel Bisulphate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation by the… | 21 sources — open the full entry |
| Clozapine | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may increase the plasma concentrations of drugs that are primarily metabolized… | 9 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the blood concentrations and efficacy of cyclosporine. The… | 20 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Moderate | Metabolism | RECOMMENDED: Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of ethinyl estradiol and… | 47 sources — open the full entry |
| Darolutamide | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of darolutamide, which is a substrate of both… | 12 sources — open the full entry |
| Dasatinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of dasatinib, which is primarily metabolized by the isoenzyme. | 16 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
| Desogestrel | Moderate | Metabolism | Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of ethinyl estradiol and other… | 6 sources — open the full entry |
| Dexamethasone | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are…2 documented mechanisms | 19 sources — open the full entry |
| Dexamethasone + Levofloxacin | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are… | 14 sources — open the full entry |
Food & lifestyle
food
MinorAbsorption
Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.
What to do: Armodafinil should be administered on an empty stomach, at least 2 hours after or 1 hour before a meal.
2 sources
- "Product Information. Provigil (modafinil)." Cephalon, Inc (2001):
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Conditions
Conditions in which Armodafinil needs care, as documented in this source.
Alcoholism
ModeratePatients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity. Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.
1 source
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Bipolar Disorder
ModerateCentral nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression). Close monitoring is recommended when using these agents in patients with bipolar disorders.
12 sources
- "Product Information. Fastin (phentermine)." SmithKline Beecham (2001):
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical (2001):
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim (2001):
Show all 12 sourcesShow fewer sources
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
Cardiomyopathies
ModerateArmodafinil may cause ECG changes, chest pain, or arrhythmia. Armodafinil should be used with caution in patients with cardiovascular complications. Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. It is recommended to monitor heart rate and blood pressure during treatment with armodafinil. Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.
1 source
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Liver Diseases
ModerateIn a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients. The dosage of armodafinil should be reduced in patients with severe hepatic impairment. Close monitoring is recommended.
1 source
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Mental Disorders
ModerateArmodafinil may cause adverse psychiatric reactions. Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania. If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil. Close monitoring of psychiatric symptoms is recommended.
1 source
- "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Psychotic Disorders
ModerateCentral nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Close monitoring is recommended when using these agents in patients with psychotic disorders.
13 sources
- "Product Information. Fastin (phentermine)." SmithKline Beecham (2001):
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical (2001):
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals (2001):
- "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
- "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
- "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc (2001):
- "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
- "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim (2001):
Show all 13 sourcesShow fewer sources
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
- "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- "Product Information. Fintepla (fenfluramine)." Zogenix, Inc (2020):
Therapeutic duplication
Drug classes that overlap with Armodafinil, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Phrenilin with caffeine and codeine
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Synalgos-dc
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Dexmethylphenidate/serdexmethylphenidate
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Trezix
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Aspirin/butalbital/caffeine/codeine
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Mydayis
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Laniroif
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Nonbac
cerebral stimulants
The recommended maximum number of medicines in the 'cerebral stimulants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cerebral stimulants' category.
Example product in the source data (US market): Migergot